Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.

  • Kristoffer von Stedingk
  • Katleen De Preter
  • Jo Vandesompele
  • Rosa Noguera
  • Ingrid Øra
  • Jan Koster
  • Rogier Versteeg
  • Sven Påhlman
  • David Lindgren
  • Håkan Axelson
Publishing year: 2015
Language: English
Pages: 868-877
Publication/Series: International Journal of Cancer
Volume: 137
Issue: 4
Document type: Journal article
Publisher: John Wiley & Sons

Abstract english

Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value identifying prognostically differing subsets of high-risk patients on an individual patient basis. This gene expression signature independently contributes to the current neuroblastoma classification system, and if prospectively validated could provide further stratification of high-risk patients, and potential upfront identification of a group of patients that are in need of new/additional treatment regimens.


  • Cancer and Oncology


  • Kidney cancer research group
  • ISSN: 0020-7136
Håkan Axelson
E-mail: hakan [dot] axelson [at] med [dot] lu [dot] se


Division of Translational Cancer Research

+46 46 222 64 34

MV 404 A31A2